The Discovery Of Amgen's Novel Investigational KRAS(G12C) Inhibitor AMG 510 Published In Nature
Deconstructing the KRAS+ market opportunity
The Discovery Of Amgen's Novel Investigational KRASG12C Inhibitor AMG 510
Cancer Drug Discovered with ALS Help Enters Phase 2 Trials - Biosciences Area
Cancers | Free Full-Text | Targeting KRAS in Cancer: Promising Therapeutic Strategies
Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors | Journal of Medicinal Chemistry
KRAS(G12C)–AMG 510 interaction dynamics revealed by all-atom molecular dynamics simulations | Scientific Reports
Amgen unveils its KRas inhibitor in human clinical trials
Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors | Journal of Medicinal Chemistry
Asco 2019 – KRAS chase heats up with Amgen data | Evaluate
Frontiers | Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity | Nature
RSC Medicinal Chemistry
World Lung 2019 – Amgen tries to keep the pace in Kras chase | Evaluate
KRAS(G12C)–AMG 510 interaction dynamics revealed by all-atom molecular dynamics simulations | Scientific Reports
The Discovery Of Amgen's Novel Investigational KRAS(G12C) Inhibitor AMG 510 Published In Nature
AMG 510 inhibits tumour growth of patient-derived xenografts, and... | Download Scientific Diagram
Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes | npj Precision Oncology
Frontiers | The Renaissance of KRAS Targeting in Advanced Non-Small-Cell Lung Cancer: New Opportunities Following Old Failures
Sotorasib - Wikipedia
SHP2 and SOS1 Targets: Additional Players in the KRAS Inhibitors Race?
CodeBreak 100: results show durability of clinical benefit with sotorasib in patients with non-small cell lung cancer - Onco Americas
Anti-Tumor Drug AMG 510 Shows Promise in Phase 1 Trial | City of Hope
Amgen unveils its KRas inhibitor in human clinical trials
